Mytide Therapeutics: Funding, Investors & Team (Sep 2026)
Mytide is committed to providing peptides to serve a diverse array of applications. During their beta phase, they intend to work closely with partners to overcome challenges in synthesizing and purifying particular classes of peptides of interest, identify useful peptide modifications, and design and construct peptide libraries. We provide initial partners access to their cloud platform for immediate ordering, properties calculator, order tracking, and interactive data display with guaranteed purities of >90%, 3 mg quantities, and 5-day turnaround of peptides up to length 40 AA.
Mytide Therapeutics has raised $7.0M across 1 funding round on record, the most recent a Series A of $7.0M announced in Mar 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mytide Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Mytide Therapeutics Funding Rounds
Mytide Therapeutics Founders and Leadership Team
Contact details for the Mytide Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Mytide Therapeutics Funding Compared to Other Biotechnology Startups
Mytide Therapeutics' latest round of $7.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mytide Therapeutics in Biotechnology and Boston
Companies Similar to Mytide Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Mytide Therapeutics Funding FAQs
What does Mytide Therapeutics do?
Mytide is committed to providing peptides to serve a diverse array of applications. During their beta phase, they intend to work closely with partners to overcome challenges in synthesizing and purifying particular classes of peptides of interest, identify useful peptide modifications, and design and construct peptide libraries. We provide initial partners access to their cloud platform for immediate ordering, properties calculator, order tracking, and interactive data display with guaranteed purities of >90%, 3 mg quantities, and 5-day turnaround of peptides up to length 40 AA.
How much funding has Mytide Therapeutics raised?
Mytide Therapeutics has raised $7.0M across 1 round on record. The most recent is a Series A of $7.0M announced in Mar 2022.
When did Mytide Therapeutics last raise funding?
Mytide Therapeutics' most recent funding round on record is a Series A of $7.0M, announced in Mar 2022.
Who founded Mytide Therapeutics?
FundedIQ lists Dale Thomas (Founder) at Mytide Therapeutics.
Where is Mytide Therapeutics headquartered?
Mytide Therapeutics is based in Boston, Massachusetts, United States.
How many employees does Mytide Therapeutics have?
Mytide Therapeutics is in the 11-50 employee band.
How does Mytide Therapeutics' funding compare to other Biotechnology startups?
Mytide Therapeutics' latest round of $7.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Mytide Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mytide Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.